What is your preferred approach to PMRT with inflammatory breast cancer with adverse risk features?
What is your preferred approach to PMRT with inflammatory breast cancer with adverse risk features (i.e. age <45, close/positive margins or poor response to neoadjuvant therapy)?
2 Answers
Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on
Our approach is same of 50 Gy in 25 fractions to CW and Regional node with higher boost dose of 10-16 Gy
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · Mayo Clinic, Rochester, MN
Answered on
Inflammatory breast cancer is most commonly triple negative or HER2 amplified disease. Patients with significant residual disease after preoperative chemotherapy have extremely high rates of relapse. Participation on SWOG1706 (NCT03598257, @Dr. First Last PI), a phase II randomized trial of olaparib...
Join for free or sign in to see the full answer